UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of July 2024
Commission File Number 001-41231
TC BIOPHARM (HOLDINGS) PLC
(Translation of registrant’s name into English)
Maxim 1, 2 Parklands Way
Holytown, Motherwell, ML1 4WR
Scotland, United Kingdom
+44 (0) 141 433 7557
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| ☒ Form 20-F | ☐ Form 40-F |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐
Results of Annual General Meeting
On July 24, 2024, TC BioPharm (Holdings) plc (“TC BioPharm” or the “Company”) held its 2024 Annual General Meeting of its Ordinary Shareholders (the “Annual General Meeting”), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on July 1, 2024 were duly proposed and passed on a poll.
The matters presented for a vote and the related results are as follows:
| Ordinary Resolutions | Votes For | Votes Against | Votes Abstained | |||||||||
Resolution 1: To receive the Company’s annual report and audited financial statements for the year ended December 31, 2023 (the “2023 U.K. Annual Report”). | 4,527,394 | 74,280 | 121,500 | |||||||||
Resolution 2: To receive and approve the Directors’ Remuneration Report for the year ended December 31, 2023, which is set forth in the 2023 U.K. Annual Report. | 4,081,914 | 502,200 | 139,060 | |||||||||
Resolution 3: To ratify the appointment of Marcum LLP, as our U.S. independent registered public accounting firm for the year ending December 31, 2024. | 4,528,314 | 74,660 | 120,200 | |||||||||
Resolution 4: To re-appoint Ecovis Wingrave Yeats (“Ecovis”) as our U.K. statutory auditor of the Company, to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company at which the Company’s financial statements are laid before the Company. | 4,533,394 | 88,780 | 101,000 | |||||||||
Resolution 5: To authorise the Audit Committee to determine the remuneration of the U.K. statutory auditor for the year ending December 31, 2024. | 4,404,834 | 120,200 | 198,140 | |||||||||
Resolution 6: To adjourn the AGM to a later date or dates (and on more than one occasion), if necessary, to permit further solicitation of proxies if, at the time of the Meeting, there are insufficient persons present in person and/or by proxy at the Meeting to pass any of the Ordinary Resolutions set forth herein. | 3,961,254 | 640,960 | 120,960 | |||||||||
The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to ordinary shareholders on July 1, 2024 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on July 1, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TC BIOPHARM (HOLDINGS) PLC | ||
| Date: July 29, 2024 | By: | /s/ Martin Thorp |
| Martin Thorp | ||
| Chief Financial Officer | ||